Nguyen, B.
09/846342


```
     FILE 'REGISTRY' ENTERED AT 11:52:55 ON 19 FEB 2004
L1          164 SEA ABB=ON  PLU=ON  GDFLAEGGGVR/SQSP
     FILE 'HCAPLUS' ENTERED AT 11:53:21 ON 19 FEB 2004
L2          103 SEA ABB=ON  PLU=ON  L1
L3           12 SEA ABB=ON  PLU=ON  L2 AND MARKER
L4           19 SEA ABB=ON  PLU=ON  L2 AND (INDICAT? OR DIAGNOS? OR
                DETERM? OR DET## OR DETECT? OR SCREEN?)(S)(DISEAS? OR
                DISORDER)
L5           22 SEA ABB=ON  PLU=ON  L3 OR L4
```

L5 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:39697 HCAPLUS

TITLE: Human prostate cancer marker genes associated with various metastatic stages identified by gene profiling, and related compositions, kits, and methods for diagnosis, prognosis and therapy

INVENTOR(S): Schlegel, Robert; Endege, Wilson O.

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 131 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611
US 2004009481	A1	20040115	US 2002-166883	20020611

PRIORITY APPLN. INFO.: US 2001-297285P P 20010611
US 2002-166883 A 20020611

AB The invention relates to compns., kits, and methods for diagnosing, staging, prognosing, monitoring and treating human prostate cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of prostate cancer. In particular, three sets of the marker genes set, corresponding to 11617 GenBank Accession Nos. (only 2168 new submissions) and 15 SEQ IDs, are identified by transcription profiling using RNA derived from clin. samples, that were expressed at least 2-fold or greater than the normal controls. Using TNM staging approach, these markers are divided to three groups, ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the liver (M stage); ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the bone (M stage); and ones can be used to determine whether prostate cancer has metastasized, or is likely to metastasize, to the lymph nodes (N stage and/or M stage). The invention also relates to a kit for assessing the specific type of metastatic prostate cancer, e.g., cancer that has metastasized to the liver, bone or lymph nodes. [This abstract record is one of three records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L5 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:454906 HCAPLUS
DOCUMENT NUMBER: 139:18402
TITLE: Genes differentially expressed in treated human C3A liver cell cultures and useful for **diagnosis** and treatment of liver **disorders**
INVENTOR(S): Kaser, Matthew R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003108871	A1	20030612	US 2001-919039	20010730
PRIORITY APPLN. INFO.:			US 2000-222113P P	20000728

AB The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in treated human C3A liver cell cultures and which may be used entirely or in part to **diagnose**, to stage, to treat, or to monitor the progression or treatment of liver **disorders** such as hyperlipidemia, type II diabetes, and tumors of the liver. The human C3A cell line is a clonal derivative of HepG2/C3 (hepatoma cell line), which was selected for strong contact inhibition of growth. Gene expression changes in C3A cells in response to clofibrate, fenofibrate, captopril, enalapril, dexamethasone, diethylstilbestrol, 3-methylcholanthrene, LY294002, and insulin plus LY294002 are provided.

IT **536781-69-8P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; genes differentially expressed in treated human C3A liver cell cultures and useful for **diagnosis** and treatment of liver **disorders**)

L5 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:448590 HCAPLUS
Correction of: 2003:177122
DOCUMENT NUMBER: 139:31810
Correction of: 138:216594
TITLE: Differentially expressed nucleic acids and their encoded proteins associated with pain and their use in screening for regulatory agents
INVENTOR(S): Woolf, Clifford; D'Urso, Donatella; Befort, Katia; Costigan, Michael
PATENT ASSIGNEE(S): The General Hospital Corporation, USA; Bayer AG
SOURCE: PCT Int. Appl., 1017 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016475	A2	20030227	WO 2002-XC25765	20020814

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003016475	A2	20030227	WO 2002-US25765	20020814

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
US 2001-312147P	P	20010814
US 2001-346382P	P	20011101
US 2001-333347P	P	20011126
WO 2002-US25765	A	20020814

AB The present invention relates to human and rat nucleic acid sequences which are related to pain and which are differentially expressed during pain. The nucleic acids are differentially expressed by at least ±1.4-fold in any or all of the following conditions using the Affymetrix human U95, murine U74 and rat U34 GeneChip arrays: axotomy, spared nerve injury, chronic construction, spinal segmental nerve lesion, and inflammatory pain models. The invention further relates to methods of identifying nucleic acid sequences which are differentially expressed during pain, microarrays comprising such differentially expressed sequences, and methods of screening agents for the ability to regulate the expression of such differentially expressed sequences. [This abstract record is one of seven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **540844-29-9**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; differentially expressed nucleic acids and their encoded proteins associated with pain and their use in screening for regulatory agents)

L5 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:282303 HCAPLUS
DOCUMENT NUMBER: 138:316490
TITLE: Nucleic acid molecules, polypeptides and uses therefor, including **diagnosis** and treatment of Alzheimer's **disease** in human
INVENTOR(S): Durham, L. Kathryn; Friedman, David L.; Herath, Herath Mudiyanselage Athula Chandrasiri; Kimmel, Lida H.; Parekh, Rajesh Bhikhu; Potter, David M.; Rohlff, Christian; Silber, B. Michael; Snyder, Peter Jeffrey; Soares, Holly Daria; Stiger, Thomas R.; Sunderland, P. Trey; Townsend, Robert Reid; White, W. Frost; Williams, Stephen A.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Oxford Glycosciences (Uk) Ltd.
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028543	A2	20030410	WO 2002-US31642	20021003
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003284574	A2	20031007	JP 2002-291568	20021003
US 2004022794	A1	20040205	US 2002-264309	20021003

PRIORITY APPLN. INFO.: US 2001-326708P P 20011003

AB The present invention provides methods and compns. for **screening, diagnosis** and prognosis of Alzheimer's **disease**, for monitoring the effectiveness of Alzheimer's **disease** treatment, and for drug development. The invention relates to the identification of protein and protein isoforms that are associated with predisposition to Alzheimer's **Disease** and its onset and development, and of genes and nucleic acid mols., encoding the same, and to their use for e.g., clin. **screening, diagnosis**, treatment, as well as for drug **screening** and drug development. Alzheimer's **Disease**-Associated features (AFs), **detectable** by two-dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Alzheimer's **Disease**-Associated Protein Isoforms (APIs) **detectable**

in cerebrospinal fluid, serum or plasma, prepns. comprising isolated APIs antibodies immunospecific for APIs, pharmaceutical compns., **diagnostic** and therapeutic methods, and kits comprising or based on the same.

IT **25422-31-5**, Fibrinopeptide A (human)
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide; nucleic acid mols., polypeptides and uses therefor, including **diagnosis** and treatment of Alzheimer's **disease** in human)

L5 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:221817 HCAPLUS
DOCUMENT NUMBER: 138:249915
TITLE: Human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Zhong, Mei; Li, Li; Gorman, Linda; Spytek, Kimberly A.; Kekuda, Ramesh; Taupier, Raymond J., Jr.; Anderson, David W.; Vernet, Corine A. M.; Catterton, Elina; Miller, Charles E.; Shenoy, Suresh G.; Patturajan, Meera; Pena, Carol E. A.; Tchernev, Velizar T.; Padigaru, Muralidhara; Gusev, Vladimir Y.; Malyankar, Uriel M.; Burgess, Catherine E.; Gerlach, Valerie L.; Casman, Stacie J.; Rieger, Daniel K.; Grosse, William M.; Smithson, Glennda; Peyman, John A.; Starling, Gary; Rothenberg, Mark E.; Larochelle, William J.; Shimkets, Richard A.; Crabtree, Julie; Rastelli, Luca; Voss, Edward Z.; Boldog, Ferenc L.; Edinger, Shlomit R.; Millet, Isabelle; MacDougall, John R.; Ellerman, Karen; Chapoval, Andrei
PATENT ASSIGNEE(S): Curagen Corporation, USA
SOURCE: PCT Int. Appl., 849 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 105
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003023008	A2	20030320	WO 2002-US28596	20020909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003150003	A1	20030807	US 2002-229834	20020827

PRIORITY APPLN. INFO.: US 2001-318120P P 20010907

US 2001-318130P P 20010907
US 2001-318219P P 20010907
US 2001-318430P P 20010910
US 2001-318765P P 20010912
US 2001-322781P P 20010917
US 2001-322816P P 20010917
US 2001-323519P P 20010919
US 2001-323631P P 20010920
US 2001-323636P P 20010920
US 2001-324969P P 20010925
US 2001-325091P P 20010925
US 2001-324990P P 20010926
US 2002-357303P P 20020215
US 2002-360973P P 20020228
US 2002-366131P P 20020320
US 2002-367753P P 20020325
US 2002-369479P P 20020402
US 2002-379532P P 20020510
US 2002-381664P P 20020517
US 2002-381672P P 20020517
US 2002-383651P P 20020528
US 2002-384012P P 20020529
US 2002-390155P A2 20020619

AB Disclosed herein are 127 cDNA sequences that encode novel human polypeptides that are members of various protein families. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivs., variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, **diagnostic** and research methods for **diagnosis**, treatment, and prevention of **disorders** involving any one of these novel human nucleic acids and proteins.

IT **502942-44-1P 502942-46-3P 502942-48-5P**
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human cDNA sequences and their encoded proteins and diagnostic and therapeutic uses)

L5 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:97550 HCAPLUS
DOCUMENT NUMBER: 138:164674
TITLE: Molecular **markers** for hepatocellular carcinoma and their use in diagnosis and therapy
INVENTOR(S): Debuschewitz, Sabine; Jobst, Juergen; Kaiser, Stephan
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010336	A2	20030206	WO 2002-EP8305	20020725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10136273	A1	20030213	DE 2001-10136273	20010725
WO 2004011945	A2	20040205	WO 2003-EP8243	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: DE 2001-10136273 A 20010725
WO 2002-EP8305 A 20020725

AB The invention relates to mol. **markers** occurring for hepatocellular carcinoma. The invention more particularly comprises gene sequences or peptides coded thereby which can be regulated upwards or downwards for hepatic cell carcinoma (HCC) in relation to healthy, normal liver cells in the expression thereof. The invention also relates to the use of said sequences in the diagnosis and/or therapy of HCC and for screening purposes in order to identify novel active ingredients for HCC. The invention also relates to an HCC specific cluster as a unique diagnostic agent for HCC.

IT **481122-84-3 481122-85-4**, Fibrinogen alpha subunit (human)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; mol. **markers** for hepatocellular carcinoma)

L5 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:849921 HCAPLUS
DOCUMENT NUMBER: 137:348842
TITLE: Polymer **marker indicative** of **disease** state having a molecular weight of 1518 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Syn.X Pharma, Inc., Can.
SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088716	A2	20021107	WO 2002-CA577	20020425
WO 2002088716	A3	20031023		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845765 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer.

IT **25422-31-5**, Fibrinopeptide A (human)
RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(polymer **marker indicative** of **disease** state having a mol. weight of 1518 daltons)

L5 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833553 HCAPLUS
DOCUMENT NUMBER: 137:334913
TITLE: Alpha fibrinogen biopolymer **marker** indicative of renal failure having a molecular weight of 1206 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2002161185 A1 20021031 US 2001-845725 20010430
US 6627608 B2 20030930
WO 2002088721 A2 20021107 WO 2002-CA609 20020426
WO 2002088721 A3 20021227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-845725 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence EGDFLAEGGGVR and characterized as a α fibrinogen having a mol. weight of 1206 daltons was found. This **marker** is indicative of renal failure.

IT **59001-24-0**, 5-16-Fibrinopeptide A (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha fibrinogen biopolymer **marker** of 1206 daltons indicative of renal failure)

L5 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833547 HCAPLUS
DOCUMENT NUMBER: 137:334907
TITLE: Alpha fibrinogen biopolymer **marker** indicative of renal failure or intracerebral hemorrhage having a molecular weight of 1465 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2002161179	A1	20021031	US 2001-845719	20010430
US 6627606	B2	20030930		
WO 2002088715	A2	20021107	WO 2002-CA576	20020425
WO 2002088715	A3	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-845719 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence DSGEGDFLAEGGGVR and characterized as a α fibrinogen having a mol. weight of 1465 daltons was found. This **marker** is indicative of renal failure or intracerebral hemorrhage.

IT **107012-96-4**, 2-16-Fibrinopeptide A (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha fibrinogen biopolymer **marker** of 1465 daltons indicative of renal failure or intracerebral hemorrhage)

L5 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833398 HCAPLUS
DOCUMENT NUMBER: 137:334899
TITLE: Alpha fibrinogen biopolymer **marker** indicative of myocardial infarction having a molecular weight of 1536 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2002160423	A1	20021031	US 2001-846780	20010430
WO 2002088718	A2	20021107	WO 2002-CA579	20020425
WO 2002088718	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-846780 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence ADSGEGDFLAEGGGVR and characterized as a α fibrinogen having a mol. weight of 1536 daltons was found. This **marker** is indicative of myocardial infarction.

IT **25422-31-5**, Fibrinopeptide A (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha fibrinogen biopolymer **marker** of 1536 daltons indicative of myocardial infarction)

L5 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833397 HCAPLUS
DOCUMENT NUMBER: 137:334898
TITLE: Alpha fibrinogen biopolymer **marker** indicative of myocardial infarction having a molecular weight of 1077 daltons
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2002160422 A1 20021031 US 2001-846342 20010430
WO 2002088708 A2 20021107 WO 2002-CA620 20020429
WO 2002088708 A3 20031023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2001-846342 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular **disease** state; thereby enabling a **diagnostician** to gain the ability to characterize either the presence or absence of said at least one **disease** state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific **marker** identified by the sequence GDFLAEGGGVR and characterized as a α fibrinogen having a mol. weight of 1077 daltons was found. This **marker** is indicative of myocardial infarction.

IT **473551-61-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(alpha fibrinogen biopolymer **marker** of 1077 daltons indicative of myocardial infarction)

L5 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:833395 HCAPLUS
DOCUMENT NUMBER: 137:348834
TITLE: Process for diagnosis of physiological conditions by characterization of proteomic materials
INVENTOR(S): Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; Vrees, Tammy
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 25 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002160420	A1	20021031	US 2001-846330	20010430

WO 2002088744 A2 20021107 WO 2002-CA623 20020429
WO 2002088744 A3 20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1384082 A2 20040128 EP 2002-766587 20020429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2001-846330 A 20010430
WO 2002-CA623 W 20020429

AB The present invention discloses the use of proteomic investigation as a diagnostic tool; and particularly teaches the use of proteomic investigative techniques and methodol. to determine a proteomic basis for the development and progression of abnormal physiol. conditions and the development and characterization of risk assessment, diagnostic and therapeutic means and methodologies. Serum samples from patients suffering from a variety of diseases in Syndrome X were analyzed by SELDI mass spectrometry using the Ciphergen PROTEINCHIP system to discern disease **markers.**

IT **474451-04-2 474451-05-3 474451-07-5**
474451-13-3 474451-14-4
RL: PRP (Properties)
(unclaimed sequence; process for diagnosis of physiol. conditions by characterization of proteomic materials)

L5 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:575357 HCAPLUS
DOCUMENT NUMBER: 137:123577
TITLE: Screening relative abundance of multiple sclerosis associated protein isoforms by two-dimensional gel electrophoresis for diagnosis and treatment of multiple sclerosis
INVENTOR(S): Herath, Herath Mudiyanselage Athula Chandrasiri; Perekh, Rajesh Bhikhu; Rohlff, Christian
PATENT ASSIGNEE(S): Oxford Glycosciences (UK) Ltd., UK
SOURCE: PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059604	A2	20020801	WO 2002-GB330	20020125
WO 2002059604	C1	20021121		
WO 2002059604	A3	20030703		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1354199 A2 20031022 EP 2002-715572 20020125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-264404P P 20010126
US 2001-331647P P 20011120
WO 2002-GB330 W 20020125

AB The present invention provides methods and compns. for screening, diagnosis and prognosis of multiple sclerosis, for monitoring the effectiveness of multiple sclerosis treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Multiple Sclerosis-Associated Features (MSFs), detectable by two-dimensional electrophoresis of body fluid e.g. cerebrospinal fluid are described. The invention further provides Multiple Sclerosis-Associated Protein Isoforms (MSPIs) detectable in body fluid e.g. cerebrospinal fluid, prepns. comprising isolated MSPIs, antibodies immunospecific for MSPIs, and kits containing the same. MSPIs in cerebrospinal fluid are separated by isoelec. focusing followed by SDS-PAGE for patients in whom no **disease** or pathol. is **detected** and in patients having multiple sclerosis. A two-dimensional array is generated by separating biomols. on a two-dimensional gel according to their electrophoretic mobility and isoelec. point. A computer-generated digital profile of the array is generated, representing the identity, apparent mol. weight, isoelec. point, and relative abundance of a plurality of proteins detected in the two-dimensional array, thereby permitting computer mediated comparison of profiles from multiple biol. samples, as well as computer aided excision of separated proteins of interest. Numerous MSPIs are identified. Tryptic peptide digest sequences and genes encoding the same are provided. The MSPIs have use for clin. screening, diagnosis, prognosis, therapy an prophylaxis, as well as for drug screening and development of pharmaceutical products.

IT **25422-31-5**, Fibrinopeptide A (human)
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(MSPI tryptic digest peptide sequence; screening relative abundance of multiple sclerosis associated protein isoforms by two-dimensional gel electrophoresis for diagnosis and treatment of multiple sclerosis)

L5 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:488143 HCAPLUS
DOCUMENT NUMBER: 137:42668
TITLE: Human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies
INVENTOR(S): Rosen, Craig A.; Ruben, Steven M.

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 196 pp., Cont.-in-part of Appl. No. PCT/US00/05989.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002081659	A1	20020627	US 2001-925297	20010810
WO 2000055320	A1	20000921	WO 2000-US5989	20000308

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-124270P P 19990312
WO 2000-US5989 A2 20000308

AB The present invention relates to 459 novel pancreatic- and pancreatic cancer-related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "pancreatic antigens," and antibodies that immunospecifically bind these polypeptides, and the use of such pancreatic polynucleotides, antigens, and antibodies for **detecting**, treating, preventing and/or prognosing **disorders** of the pancreas, including, but not limited to, the presence of pancreatic cancer and pancreatic cancer metastases. More specifically, isolated pancreatic nucleic acid mols. are provided encoding novel human pancreatic polypeptides. Novel pancreatic polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human pancreatic polynucleotides, polypeptides, and/or antibodies. The invention further relates to **diagnostic** and therapeutic methods useful for **diagnosing**, treating, preventing and/or prognosing **disorders** related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such **disorders**. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compns. for inhibiting or promoting the production and/or function of the polypeptides of the invention.

IT **438511-73-0P**
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies)

L5 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:748125 HCAPLUS
DOCUMENT NUMBER: 135:298804
TITLE: Nucleic acid molecules, polypeptides, and uses including **diagnosis** and treatment of Alzheimer's **disease**
INVENTOR(S): Durham, Kathryn L.; Friedman, David L.; Herath, Herath Mudiyanselage Athula Chandrasiri; Kimmel, Lida H.; Parekh, Rajesh Bhikhu; Potter, David M.; Rohlff, Christian; Silber, B. Michael; Stiger, Thomas R.; Sunderland, P. Trey; Townsend, Robert Reid; White, Frost; Williams, Stephen A.
PATENT ASSIGNEE(S): Oxford Glycosciences (UK) Ltd., UK; Pfizer Inc.; et al.
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001075454	A2	20011011	WO 2001-US10908	20010403
WO 2001075454	A3	20030508		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001049835	A5	20011015	AU 2001-49835	20010403
US 2002164668	A1	20021107	US 2001-826290	20010403
EP 1325338	A2	20030709	EP 2001-923111	20010403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 2000-194504P P 20000403
US 2000-253647P P 20001128
WO 2001-US10908 W 20010403

AB Methods and compns. are provided for **screening**, **diagnosis** and prognosis of Alzheimer's **disease**, for monitoring the effectiveness of Alzheimer's **disease** treatment, and for drug development. Alzheimer's **Disease** -Associated Features (AFs), **detectable** by two-dimensional electrophoresis of cerebrospinal fluid, serum, or plasma are described. The invention further provides Alzheimer's **Disease**-Associated Protein Isoforms (APIs) **detectable** in cerebrospinal fluid, serum, or plasma, prepns. comprising isolated APIs, antibodies immunospecific for APIs, pharmaceutical compns., **diagnostic** and therapeutic methods, and kits.

IT **25422-31-5**, Fibrinopeptide A (human)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(nucleic acids, polypeptides, and uses including **diagnosis** and treatment of Alzheimer's **disease**)

L5 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:687935 HCAPLUS
DOCUMENT NUMBER: 133:263203
TITLE: Assay for **marker** of human polymorphonuclear leukocyte elastase activity
INVENTOR(S): Humes, John L.; Mumford, Richard Allen; Davies, D. T. Philip; Dahlgren, Mary Ellen; Boger, Joshua Schafer
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 68 pp., Cont.-in-part of U.S. Ser. No. 335,524, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6124107	A	20000926	US 1995-469141	19950606
WO 9614580	A1	19960517	WO 1995-US13794	19951103
W: CA, JP, US, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.:

US 1988-205416	B1	19880610
US 1991-674280	B1	19910321
US 1992-902102	B1	19920622
US 1994-196663	B2	19940215
US 1994-335524	B2	19941107
US 1995-469141	A	19950606

AB A immunoassay based on the detection of leukocyte elastase-produced fibrinogen cleavage peptides which allows the evaluation of the potency of compds. that inhibit formation of cleavage peptides in a variety of in vitro cell biol. situations is provided. The new RIA detects endogenous Aα(Val360) signal using 125I-labeled epitope peptide YRGSAGHWTSESSV. The assay may be employed to detect an endogenous leukocyte elastase-produced fibrinogen cleavage peptide signal in normal human plasma and at elevated levels in cystic fibrosis plasma and in rheumatoid arthritis synovial fluid samples. The assay procedure can be a single step assay which allows for the rapid and reproducible detection of specific cleavage peptides.

IT **25422-31-5**, Fibrinopeptide A (human) **104061-55-4** **127608-19-9** **127608-20-2** **127608-25-7** **127608-26-8** **127608-27-9** **127626-59-9**
RL: PRP (Properties)
(unclaimed sequence; assay for **marker** of human polymorphonuclear leukocyte elastase activity)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE

FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L5 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:666873 HCAPLUS
DOCUMENT NUMBER: 133:233616
TITLE: Human pancreas and pancreatic cancer-associated gene sequences and polypeptides
INVENTOR(S): Rosen, Craig A.; Ruben, Steven M.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 1379 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055320	A1	20000921	WO 2000-US5989	20000308
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1159420	A1	20011205	EP 2000-914861	20000308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003514510	T2	20030422	JP 2000-605738	20000308
US 2002081659	A1	20020627	US 2001-925297	20010810

PRIORITY APPLN. INFO.: US 1999-124270P P 19990312
WO 2000-US5989 W 20000308

AB This invention relates to 459 newly identified pancreas or pancreatic cancer-related cDNAs and the polypeptides encoded by these polynucleotides herein collectively known as "pancreas cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such pancreas cancer antigens for **detection**, prevention and treatment of **disorders** of the pancreas, particularly the presence of pancreatic cancer. This invention relates to the pancreas cancer antigens as well as vectors, host cells, antibodies directed to pancreas cancer antigens, and recombinant and synthetic methods for producing the same. Also provided are **diagnostic** methods for **diagnosing** and treating, preventing and/or prognosing **disorders** related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such **disorders**. The invention further relates to screening methods for identifying agonists and antagonists of pancreas cancer antigens of the invention. The present invention further relates to methods and/or compns. for inhibiting the production and/or function of the polypeptides of the present invention.

IT **291796-37-7**

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human pancreas cancer-associated gene sequences and polypeptides)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:133731 HCAPLUS
DOCUMENT NUMBER: 132:177254
TITLE: Fibrinogen fragments, their production with recombinant cells, and their use in diagnosis and therapy
INVENTOR(S): Grieninger, Gerd; Applegate, Dianne; Stoike-Steben, Lara
PATENT ASSIGNEE(S): The New York Blood Center, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009562	A1	20000224	WO 1999-US18412	19990812
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1105428	A1	20010613	EP 1999-941108	19990812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6416963	B1	20020709	US 1999-373157	19990812
US 2002168722	A1	20021114	US 2002-112527	20020329

PRIORITY APPLN. INFO.:
US 1998-96210P P 19980812
US 1999-373157 A1 19990812
WO 1999-US18412 W 19990812

AB The invention provides novel αECX cleavage fragments of fibrinogen and methods for detecting and purifying these fragments. The method of the invention also includes a diagnostic method for determining fibrinolytic states or atherogenesis in a mammal. Methods of treating disease characterized by fibrinogen metabolism are also disclosed. In addition, the invention also provides monospecific antibodies which are specifically reactive with αEC domain of fibrinogen. Also provided, are DNA and RNA mols. that encode αECX cleavage fragments of fibrinogen. In addition, the present invention includes a vector and a host cell capable of expressing αECX cleavage fragments of fibrinogen. Thus, fibrinogen-420 was purified from human blood plasma. The behavior of fibrinogen-420 was similar to that of fibrinogen-340 in clot formation and proteolytic susceptibility. Plasmin rapidly released the αEC domain of fibrinogen-420 and this fragment was resistant to further degradation in vitro. This αEC fragment is

detectable in the plasma of patients undergoing thrombolytic therapy.

IT **259243-12-4**
RL: PRP (Properties)
(unclaimed protein sequence; fibrinogen fragments, their production with recombinant cells, and their use in diagnosis and therapy)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:759071 HCAPLUS
DOCUMENT NUMBER: 123:246833
TITLE: Thrombin inhibitors, their preparation, and their therapeutic and diagnostic use
INVENTOR(S): Maraganore, John M.; Fenton, Ii John W.; Kline, Toni
PATENT ASSIGNEE(S): Biogen, Inc., USA
SOURCE: U.S., 44 pp. Cont.-in-part of U.S. 5,196,404.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5433940	A	19950718	US 1992-834259	19920210
US 5196404	A	19930323	US 1990-549388	19900706
US 5196404	B1	19960910		
WO 9102750	A1	19910307	WO 1990-US4642	19900817
W: AU, CA, FI, HU, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
US 5425936	A	19950620	US 1992-924549	19920731
US 5514409	A	19960507	US 1995-431678	19950502
US 5691311	A	19971125	US 1995-439297	19950511

PRIORITY APPLN. INFO.:
US 1989-395482 B2 19890818
US 1990-549388 A2 19900706
WO 1990-US4642 W 19900817
US 1991-652929 A3 19910208
US 1992-834259 A3 19920210
US 1992-924549 A3 19920731

AB Biol. active mols. which bind to and inhibit thrombin are disclosed. Specifically, these mols. are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 Å in length; and a thrombin catalytic site-directed moiety (CSDM). The invention also relates to compns., combinations and methods which employ these mols. for therapeutic, prophylactic and diagnostic purposes. Synthesis of hirulogs is described. The effect of hirulog 8 [D-Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu] on thrombosis is included, as are examples of hirulog 8 binding to the active site of thrombin, in vivo anticoagulant activity, clearance times, etc.

IT **136293-59-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(thrombin inhibitors, their preparation, and their therapeutic and diagnostic use)

L5 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:632030 HCAPLUS
DOCUMENT NUMBER: 117:232030
TITLE: Suppression of immune responses with oligomeric forms of antigen of controlled chemistry
INVENTOR(S): Dintzis, Howard M.; Dintzis, Renee Z.; Blodgett, James K.; Cheronis, John C.; Kirschenheuter, Gary
PATENT ASSIGNEE(S): Johns Hopkins University, USA
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211029	A1	19920709	WO 1991-US9176	19911217
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2098281	AA	19920618	CA 1991-2098281	19911217
AU 9211526	A1	19920722	AU 1992-11526	19911217
EP 572443	A1	19931208	EP 1992-904018	19911217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06503833	T2	19940428	JP 1991-504304	19911217

PRIORITY APPLN. INFO.: US 1990-628858 A 19901217
WO 1991-US9176 A 19911217

AB A method is provided of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises (1) preparing a construct comprising ≥1 discrete antigenically recognizable moiety (corresponding to a determinant of an antigen causing the undesired immune response) bound to a pharmacol. acceptable carrier, wherein the number of moieties bound to the carrier and the spacing of the moieties on the carrier are such that the construct does not elicit an immune response to the moieties but does directly compete with the antigen for receptors on an immunocompetent cell that recognizes the determinant, the construct thereby specifically suppressing the undesired immune response; and (2) administration of the construct to the mammal in an effective amount Also disclosed are methods for preparing the constructs (scaffold synthesis, conjugate preparation, etc.). A conjugate of dextran with a peptide derivative of a histone H2B amino-terminal fragment was prepared Anti-histone antibody titers in mice that received the suppressive conjugate were suppressed to background levels, while animals receiving control conjugates showed no significant changes (or, in many cases, actual increases) in their anti-histone antibody levels. Animals treated with immunosuppressive conjugate had no detectable cells actively secreting anti-histone antibodies, while control animals had a population of anti-histone antibody-secreting cells too numerous to quantitate. Immunogenicity of a variety of other constructs (e.g. fluoresceinated polymers, benzoylpenicillin conjugate with albumin

or with ovalbumin) was examined
IT **144117-99-7**
RL: USES (Uses)
(amino acid composition of, immunosuppressant peptide-dextran conjugate preparation in relation to)

L5 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:403004 HCAPLUS
DOCUMENT NUMBER: 113:3004
TITLE: Elastase-induced fibrinogen cleavage site antigens, antibodies to them, and their immunochemical detection
INVENTOR(S): Dahlgren, Mary E.; Mumford, Richard A.; Boger, Joshua S.; Davies, D. T. Philip
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 345906	A2	19891213	EP 1989-201460	19890607
EP 345906	A3	19901122		
EP 345906	B1	19960313		
R: CH, DE, FR, GB, IT, LI, NL				
JP 02117699	A2	19900502	JP 1989-145529	19890609

PRIORITY APPLN. INFO.: US 1988-205416 A 19880610
US 1988-205417 A 19880610
US 1988-205418 A 19880610

AB Peptides are provided comprising an epitope which includes amino- or carboxy-terminal amino acid sequences of the primary cleavage products of human leukocyte elastase-cleaved human fibrinogen. The peptides are used to raise antibodies (Abs) specific for as few as 5 amino acids on either side of the enzymic cleavage site. The peptides are useful as specific probes for the detection of the above antibodies and are also used in assays for the rapid determination of in vivo and in vitro elastase cleavage products. Thus, purified human fibrinogen was treated with human neutrophil elastase, and the fragments generated were purified by HPLC. Amino acid sequence anal. allowed identification of 9 elastase cleavage sites in human fibrinogen. Peptide antigens and probes representing amino and carboxyl termini adjacent to the cleavage sites were synthesized, e.g. an antigenic peptide containing A α chain carboxyl terminal 17-21 residue sequence Gly-Pro-Arg-Val-Val (I) as epitope. Antigenic peptides were conjugated to bovine serum albumin and the conjugates were used as immunogens in production of monospecific Absolute An immunoassay for determination of the I epitope is described, as is the effect of membrane perturbation agents, e.g. Ca ionophore A23187, of I-containing peptide in whole blood.
IT **104061-55-4 127608-19-9 127608-20-2 127608-25-7 127608-26-8 127608-27-9 127626-59-9**
RL: ANST (Analytical study)

(antigen probe related to peptide epitope of elastase-cleaved human fibrinogen, antibody specificity in relation to)

L5 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:493177 HCAPLUS
DOCUMENT NUMBER: 95:93177
TITLE: Significance of fibrinopeptide A (FPA) in the diagnosis of low grade intravascular coagulation and venous thromboembolism
AUTHOR(S): Van Mourik, J. A.
CORPORATE SOURCE: Dep. Blood Coagulation Cent. Lab., Netherlands Red Cross Blood Transfus. Serv., Amsterdam, Neth.
SOURCE: Haematologica (1981), 66(3), 259-68
CODEN: HAEMAX; ISSN: 0390-6078
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 14 refs.
IT **25422-31-5**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in intravascular coagulation and venous thromboembolism diagnosis)

E1 THROUGH E28 ASSIGNED

FILE 'REGISTRY' ENTERED AT 11:57:47 ON 19 FEB 2004
L6 28 SEA FILE=REGISTRY ABB=ON PLU=ON (25422-31-5/BI OR 104061-55-4/BI OR 127608-19-9/BI OR 127608-20-2/BI OR 127608-25-7/BI OR 127608-26-8/BI OR 127608-27-9/BI OR 127626-59-9/BI OR 107012-96-4/BI OR 136293-59-9/BI OR 144117-99-7/BI OR 259243-12-4/BI OR 291796-37-7/BI OR 438511-73-0/BI OR 473551-61-0/BI OR 474451-04-2/BI OR 474451-05-3/BI OR 474451-07-5/BI OR 474451-13-3/BI OR 474451-14-4/BI OR 481122-84-3/BI OR 481122-85-4/BI OR 502942-44-1/BI OR 502942-46-3/BI OR 502942-48-5/BI OR 536781-69-8/BI OR 540844-29-9/BI OR 59001-24-0/BI)

L7 28 L1 AND L6

L7 ANSWER 1 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **540844-29-9** REGISTRY
CN Pain-regulated protein (human clone WO03016475-SEQID-14404) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 291: PN: WO03016475 SEQID: 14404 claimed protein
CI MAN
SQL 866

SEQ 1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
====== =====
51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG

```
       351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS
       401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT
       451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL
       501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE
       551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
       601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQSGIFNI
       651 KLPGSSKIFS VYCDQETSLG GWLLIQQRMD GSLNFNRTWQ DYKRGFGSLN
       701 DEGEGEFWLG NDYLHLLTQR GSVLRVELED WAGNEAYAEY HFRVGSEAEG
       751 YALQVSSYEG TAGDALIEGS VEEGAEYTSH NNMQFSTFDR DADQWEENCA
       801 EVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENG VVWVSFRGAD
       851 YSLRAVRMKI RPLVTQ
HITS AT:    25-35

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  139:31810

L7   ANSWER 2 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   536781-69-8  REGISTRY
CN   Liver disease-associated protein (human C3A cell Incyte clone
     1511658) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   121: PN: US20030108871 SEQID: 121 claimed protein
CI   MAN
SQL  644

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
                                   ======  =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
       301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG
       351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS
       401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT
       451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL
       501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE
       551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
       601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR GIHTSPLGKP SLSP
HITS AT:    25-35

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  139:18402

L7   ANSWER 3 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   502942-48-5  REGISTRY
CN   Protein NOV9c (human clone CG137873-02 precursor) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   36: PN: WO03023008 SEQID: 36 claimed protein
CI   MAN
SQL  481

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
```

```
                                      ====== =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
       301 GPGSTGSWNS GSSGTGSTGN QNPGSPRPGS TGTWNPGSSE RGSAGHWTSE
       351 SSVSGSTGQW HSESGSFRPD SPGSGNARPN NPDWGSESGI FTNTKESSSH
       401 HPGIAEFPSR GKSSSYSKQF TSSTSYNRGD STFESKSYKM ADEAGSEADH
       451 EGTHSTKRGH AKSRPVRGIH TSPLGKPSLS P
HITS AT:    25-35

REFERENCE   1:  138:249915

L7   ANSWER 4 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   502942-46-3  REGISTRY
CN   Protein NOV9b (human clone CG137873-03 precursor) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   34: PN: WO03023008 SEQID: 34 claimed protein
CI   MAN
SQL  388

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
                                      ====== =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
       301 GPGSTGSWKL EVLETKTLGA LDLVVPEPGI LAALNAEVLG TGPLRALYLV
       351 VLDNGTLNLE VLGQIAQALG TRGLTTQTGA HLKRCQEM
HITS AT:    25-35

REFERENCE   1:  138:249915

L7   ANSWER 5 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   502942-44-1  REGISTRY
CN   Protein NOV9a (human clone CG137873-01 precursor) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   32: PN: WO03023008 SEQID: 32 claimed protein
CI   MAN
SQL  644

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
                                      ====== =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
       301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG
       351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS
       401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT
       451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL
```

```
       501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE
       551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
       601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR GIHTSPLGKP SLSP
HITS AT:    25-35

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  138:249915

L7   ANSWER 6 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   481122-85-4  REGISTRY
CN   Fibrinogen alpha subunit (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1330: PN: WO03010336 TABLE: 2C claimed protein
CN   GenBank AAC97143
CN   GenBank AAC97143 (Translated from: GenBank M58569)
CI   MAN
SQL  644

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
                                   ====== =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
       301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG
       351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS
       401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT
       451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL
       501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE
       551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
       601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR GIHTSPLGKP SLSP
HITS AT:    25-35

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  138:164674

L7   ANSWER 7 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   481122-84-3  REGISTRY
CN   Fibrinogen alpha subunit precursor (human) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   1329: PN: WO03010336 TABLE: 2C claimed protein
CN   GenBank AAC97142
CN   GenBank AAC97142 (Translated from: GenBank M58569)
CI   MAN
SQL  866

SEQ      1 MFSMRIVCLV LSVVGTAWTA DSGEGDFLAE GGGVRGPRVV ERHQSACKDS
                                   ====== =====
        51 DWPFCSDEDW NYKCPSGCRM KGLIDEVNQD FTNRINKLKN SLFEYQKNNK
       101 DSHSLTTNIM EILRGDFSSA NNRDNTYNRV SEDLRSRIEV LKRKVIEKVQ
       151 HIQLLQKNVR AQLVDMKRLE VDIDIKIRSC RGSCSRALAR EVDLKDYEDQ
       201 QKQLEQVIAK DLLPSRDRQH LPLIKMKPVP DLVPGNFKSQ LQKVPPEWKA
       251 LTDMPQMRME LERPGGNEIT RGGSTSYGTG SETESPRNPS SAGSWNSGSS
```

```
       301 GPGSTGNRNP GSSGTGGTAT WKPGSSGPGS TGSWNSGSSG TGSTGNQNPG
       351 SPRPGSTGTW NPGSSERGSA GHWTSESSVS GSTGQWHSES GSFRPDSPGS
       401 GNARPNNPDW GTFEEVSGNV SPGTRREYHT EKLVTSKGDK ELRTGKEKVT
       451 SGSTTTTRRS CSKTVTKTVI GPDGHKEVTK EVVTSEDGSD CPEAMDLGTL
       501 SGIGTLDGFR HRHPDEAAFF DTASTGKTFP GFFSPMLGEF VSETESRGSE
       551 SGIFTNTKES SSHHPGIAEF PSRGKSSSYS KQFTSSTSYN RGDSTFESKS
       601 YKMADEAGSE ADHEGTHSTK RGHAKSRPVR DCDDVLQTHP SGTQSGIFNI
       651 KLPGSSKIFS VYCDQETSLG GWLLIQQRMD GSLNFNRTWQ DYKRGFGSLN
       701 DEGEGEFWLG NDYLHLLTQR GSVLRVELED WAGNEAYAEY HFRVGSEAEG
       751 YALQVSSYEG TAGDALIEGS VEEGAEYTSH NNMQFSTFDR DADQWEENCA
       801 EVYGGGWWYN NCQAANLNGI YYPGGSYDPR NNSPYEIENG VVWVSFRGAD
       851 YSLRAVRMKI RPLVTQ
HITS AT:    25-35

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

REFERENCE   1:  138:164674

L7   ANSWER 8 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   474451-14-4  REGISTRY
CN   Glycine, L-threonyl-L-alanyl-L-α-aspartyl-L-serylglycyl-L-
     α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-
     alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginyl- (9CI)
     (CA INDEX NAME)
OTHER NAMES:
CN   13: PN: US20020160420 PAGE: 15 unclaimed sequence
SQL  18

SEQ      1 TADSGEGDFL AEGGGVRG
             ==== =======
HITS AT:    7-17

REFERENCE   1:  137:348834

L7   ANSWER 9 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   474451-13-3  REGISTRY
CN   Glycine, L-alanyl-L-α-aspartyl-L-serylglycyl-L-α-
     glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-
     α-glutamylglycylglycylglycyl-L-valyl-L-arginyl- (9CI)  (CA
     INDEX NAME)
OTHER NAMES:
CN   10: PN: US20020160420 PAGE: 14 unclaimed sequence
SQL  17

SEQ      1 ADSGEGDFLA EGGGVRG
            ===== ======
HITS AT:    6-16

REFERENCE   1:  137:348834

L7   ANSWER 10 OF 28  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   474451-07-5  REGISTRY
CN   Glycine, glycyl-L-α-glutamylglycyl-L-α-aspartyl-L-
     phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-
     L-valyl-L-arginyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
```

CN 4: PN: US20020160420 PAGE: 10 unclaimed sequence
SQL 14

SEQ 1 GEGDFLAEGG GVRG
========= ===
HITS AT: 3-13

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:348834

L7 ANSWER 11 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474451-05-3** REGISTRY
CN Glycine, L-α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2: PN: US20020160420 PAGE: 10 unclaimed sequence
SQL 13

SEQ 1 EGDFLAEGGG VRG
========== ==
HITS AT: 2-12

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:348834

L7 ANSWER 12 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **474451-04-2** REGISTRY
CN Glycine, glycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020160420 PAGE: 10 unclaimed sequence
SQL 12

SEQ 1 GDFLAEGGGV RG
========== =
HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:348834

L7 ANSWER 13 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **473551-61-0** REGISTRY
CN L-Arginine, glycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020160422 PAGE: 7 claimed protein
SQL 11

SEQ 1 GDFLAEGGGV R
========== =

HITS AT: 1-11

REFERENCE 1: 137:334898

L7 ANSWER 14 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **438511-73-0** REGISTRY
CN Pancreas tumor-associated protein (human clone HLICN22 fragment) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 587: PN: US20020081659 SEQID: 587 claimed protein
CI MAN
SQL 360

SEQ 1 LNPGRPARPV LLRSXAPPLE KMFSMRIVCL VLSVVGTAWT ADSGEGDFLA
=====
51 EGGGVRGPRV VERHQSACKD SDWPFCSDED WNYKCPSGCR MKGLIDEVNQ
======
101 DFTNRINKLK NSLFEYQKNN KDSHSLTTNI MEILRGDFSS ANNRDNTYNR
151 VSEDLRSRIE VLKRKVIEKV QHIQLLQKNV RAQLVDMKRL EVDIDIKIRS
201 CRGSCSRALA REVDLKDYED QQKQLEQVIA KDLLPSRDRQ HLPLIKMKPV
251 PDLVPGNFKS QLQKVPPEWK ALTDMPQMRM ELERPGGNEI TRGGSTSYGT
301 GSETESPRNP SSAGXWNSGS SGTWXXXNLE TWELWTWKXW KLELWELWNW
351 KYWKPKPWEP
HITS AT: 46-56

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:42668

L7 ANSWER 15 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **291796-37-7** REGISTRY
CN Pancreas tumor-associated protein (human clone HLICN22) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 589: PN: WO0055320 SEQID: 587 claimed protein
CI MAN
SQL 360

SEQ 1 LNPGRPARPV LLRSXAPPLE KMFSMRIVCL VLSVVGTAWT ADSGEGDFLA
=====
51 EGGGVRGPRV VERHQSACKD SDWPFCSDED WNYKCPSGCR MKGLIDEVNQ
======
101 DFTNRINKLK NSLFEYQKNN KDSHSLTTNI MEILRGDFSS ANNRDNTYNR
151 VSEDLRSRIE VLKRKVIEKV QHIQLLQKNV RAQLVDMKRL EVDIDIKIRS
201 CRGSCSRALA REVDLKDYED QQKQLEQVIA KDLLPSRDRQ HLPLIKMKPV
251 PDLVPGNFKS QLQKVPPEWK ALTDMPQMRM ELERPGGNEI TRGGSTSYGT
301 GSETESPRNP SSAGXWNSGS SGTWXXXNLE TWELWTWKXW KLELWELWNW
351 KYWKPKPWEP
HITS AT: 46-56

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 133:233616

L7 ANSWER 16 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **259243-12-4** REGISTRY

CN 4: PN: WO0009562 SEQID: 4 unclaimed protein (9CI) (CA INDEX NAME)
CI MAN
SQL 847

SEQ 1 ADSGEGDFLA EGGGVRGPRV VERHQSACKD SDWPFCSDED WNYKCPSGCR
===== ======
51 MKGLIDEVNQ DFTNRINKLK NSLFEYQKNN KDSHSLTTNI MEILRGDFSS
101 ANNRDNTYNR VSEDLRSRIE VLKRKVIEKV QHIQLLQKNV RAQLVDMKRL
151 EVDIDIKIRS CRGSCSRALA REVDLKDYED QQKQLEQVIA KDLLPSRDRQ
201 HLPLIKMKPV PDLVPGNFKS QLQKVPPEWK ALTDMPQMRM ELERPGGNEI
251 TRGGSTSYGT GSETESPRNP SSAGSWNSGS SGPGSTGNRN PGSSGTGGTA
301 TWKPGSSGPG STGSWNSGSS GTGSTGNQNP GSPRPGSTGT WNPGSSERGS
351 AGHWTSESSV SGSTGQWHSE SGSFRPDSPG SGNARPNNPD WGTFEEVSGN
401 VSPGTRREYH TEKLVTSKGD KELRTGKEKV TSGSTTTTRR SCSKTVTKTV
451 IGPDGHKEVT KEVVTSEDGS DCPEAMDLGT LSGIGTLDGF RHRHPDEAAF
501 FDTASTGKTF PGFFSPMLGE FVSETESRGS ESGIFTNTKE SSSHHPGIAE
551 FPSRGKSSSY SKQFTSSTSY NRGDSTFESK SYKMADEAGS EADHEGTHST
601 KRGHAKSRPV RDCDDVLQTH PSGTQSGIFN IKLPGSSKIF SVYCDQETSL
651 GGWLLIQQRM DGSLNFNRTW QDYKRGFGSL NDEGEGEFWL GNDYLHLLTQ
701 RGSVLRVELE DWAGNEAYAE YHFRVGSEAE GYALQVSSYE GTAGDALIEG
751 SVEEGAEYTS HNNMQFSTFD RDADQWEENC AEVYGGGWWY NNCQAANLNG
801 IYYPGGSYDP RNNSPYEIEN GVVWVSFRGA DYSLRAVRMK IRPLVTQ
HITS AT: 6-16

REFERENCE 1: 132:177254

L7 ANSWER 17 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **144117-99-7** REGISTRY
CN D-Tyrosine, N-acetyl-S-(6-amino-1-oxohexyl)-L-cysteinyl-L-alanyl-L-α-aspartyl-L-serylglycyl-L-α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginylglycyl-L-prolyl-L-arginyl-L-valyl-L-valyl-L-valyl- (9CI) (CA INDEX NAME)
SQL 24

SEQ 1 CADSGEGDFL AEGGGVRGPR VVVY
==== =======
HITS AT: 7-17

REFERENCE 1: 117:232030

L7 ANSWER 18 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **136293-59-9** REGISTRY
CN L-Leucine, N-acetylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Hirulog α 1
SQL 28

SEQ 1 GDFLAEGGGV RPGGGGNGDF EEIPEEYL
========== =
HITS AT: 1-11

REFERENCE 1: 123:246833

REFERENCE 2: 116:165761

REFERENCE 3: 115:150383

L7 ANSWER 19 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127626-59-9** REGISTRY
CN Fibrinopeptide A (human), 16a-glycine-16b-L-proline-16c-L-arginine- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 54: PN: US6124107 SEQID: 54 unclaimed sequence
SQL 19

SEQ 1 ADSGEGDFLA EGGGVRGPR
===== ======
HITS AT: 6-16

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 20 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127608-27-9** REGISTRY
CN Fibrinopeptide A (human), 16a-glycine-16b-L-proline- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 55: PN: US6124107 SEQID: 55 unclaimed sequence
SQL 18

SEQ 1 ADSGEGDFLA EGGGVRGP
===== ======
HITS AT: 6-16

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 21 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127608-26-8** REGISTRY
CN Fibrinopeptide A (human), 16a-glycine-16b-L-proline-16c-L-arginine-16d-L-valine- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 53: PN: US6124107 SEQID: 53 unclaimed sequence
SQL 20

SEQ 1 ADSGEGDFLA EGGGVRGPRV
===== ======
HITS AT: 6-16

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 22 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127608-25-7** REGISTRY
CN Fibrinopeptide A (human), 16a-glycine-16b-L-proline-16c-L-arginine-16d-L-valine-16e-L-valine-16f-L-glutamic acid- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 52: PN: US6124107 SEQID: 52 unclaimed sequence
SQL 22

SEQ 1 ADSGEGDFLA EGGGVRGPRV VE
===== ======
HITS AT: 6-16

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 23 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127608-20-2** REGISTRY
CN L-Valine, L-α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-L-arginylglycyl-L-prolyl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 46: PN: US6124107 SEQID: 46 unclaimed sequence
SQL 17

SEQ 1 EGDFLAEGGG VRGPRVV
========= ==
HITS AT: 2-12

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 24 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **127608-19-9** REGISTRY
CN Fibrinopeptide A (human), N-L-tyrosyl-16a-glycine-16b-L-proline-16c-L-arginine-16d-L-valine-16e-L-valine- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 44: PN: US6124107 SEQID: 44 unclaimed sequence
SQL 22

SEQ 1 YADSGEGDFL AEGGGVRGPR VV
==== =======
HITS AT: 7-17

REFERENCE 1: 133:263203

REFERENCE 2: 113:3004

L7 ANSWER 25 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **107012-96-4** REGISTRY
CN 2-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Arginine, N2-[N-[N-[N-[N-[N-[N-[N-[N-[N-[N-[N-(N-α-

aspartylseryl)glycyl]-α-glutamyl]glycyl]-α-aspartyl]-3-phenylalanyl]leucyl]alanyl]-α-glutamyl]glycyl]glycyl]glycyl]valyl]- (7CI)
CN L-Arginine, L-α-aspartyl-L-serylglycyl-L-α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-
OTHER NAMES:
CN 1: PN: US20020161179 PAGE: 7 claimed protein
SQL 15

SEQ 1 DSGEGDFLAE GGGVR
====== =====
HITS AT: 5-15

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:334907

REFERENCE 2: 131:349511

L7 ANSWER 26 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **104061-55-4** REGISTRY
CN Fibrinopeptide A (human), 16a-glycine-16b-L-proline-16c-L-arginine-16d-L-valine-16e-L-valine- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 45: PN: US6124107 SEQID: 45 unclaimed sequence
SQL 21

SEQ 1 ADSGEGDFLA EGGGVRGPRV V
===== ======
HITS AT: 6-16

REFERENCE 1: 133:263203

REFERENCE 2: 117:42910

REFERENCE 3: 116:17971

REFERENCE 4: 115:227619

REFERENCE 5: 113:3004

REFERENCE 6: 111:169904

REFERENCE 7: 105:113121

L7 ANSWER 27 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **59001-24-0** REGISTRY
CN 5-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Fibrinopeptide A (human), 1-de-L-alanine-2-de-L-aspartic acid-3-de-L-serine-4-deglycine-
OTHER NAMES:
CN 1: PN: US20020161185 PAGE: 7 claimed protein
CI COM
SQL 12

SEQ 1 EGDFLAEGGG VR
========= ==
HITS AT: 2-12

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:334913

REFERENCE 2: 84:149054

L7 ANSWER 28 OF 28 REGISTRY COPYRIGHT 2004 ACS on STN
RN **25422-31-5** REGISTRY
CN Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1: PN: US20020160423 PAGE: 7 claimed protein
CN 1: PN: WO02088716 SEQID: 1 claimed protein
CN 257: PN: WO0175454 TABLE: 5 claimed protein
CN 26: PN: WO02055554 SEQID: 25 unclaimed sequence
CN 2: PN: WO03065997 SEQID: 2 claimed protein
CN 32: PN: WO03028543 SEQID: 8 claimed sequence
CN 450: PN: WO0069900 SEQID: 1135 unclaimed sequence
CN 48: PN: WO03099848 SEQID: 39 unclaimed sequence
CN 56: PN: US6124107 SEQID: 56 unclaimed sequence
CN 5: PN: WO02059604 SEQID: 5 claimed protein
CN Human fibrinopeptide A
CN L-Arginine, L-alanyl-L-α-aspartyl-L-serylglycyl-L-α-glutamylglycyl-L-α-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-α-glutamylglycylglycylglycyl-L-valyl-
CI COM
SQL 16

SEQ 1 ADSGEGDFLA EGGGVR
===== ======
HITS AT: 6-16

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 140:13435

REFERENCE 2: 139:185608

REFERENCE 3: 138:316490

REFERENCE 4: 137:348842

REFERENCE 5: 137:334899

REFERENCE 6: 137:123577

REFERENCE 7: 137:88438

REFERENCE 8: 136:247871

REFERENCE 9: 135:298804

REFERENCE 10: 134:21425

FILE 'HOME' ENTERED AT 11:58:32 ON 19 FEB 2004

Searcher : Shears 571-272-2528